CA3124267A1 - New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof - Google Patents

New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof Download PDF

Info

Publication number
CA3124267A1
CA3124267A1 CA3124267A CA3124267A CA3124267A1 CA 3124267 A1 CA3124267 A1 CA 3124267A1 CA 3124267 A CA3124267 A CA 3124267A CA 3124267 A CA3124267 A CA 3124267A CA 3124267 A1 CA3124267 A1 CA 3124267A1
Authority
CA
Canada
Prior art keywords
cancer
compound
group
stat3
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3124267A
Other languages
English (en)
French (fr)
Inventor
Patrick Thomas Gunning
Siawash AHMAR
David Rosa
Gary TIN
Mulu Gelepu
Ji Sung Park
Elvin D. De Araujo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toronto
Janpix Ltd
Original Assignee
University of Toronto
Janpix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toronto, Janpix Ltd filed Critical University of Toronto
Publication of CA3124267A1 publication Critical patent/CA3124267A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3124267A 2018-12-21 2019-12-20 New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof Pending CA3124267A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862783741P 2018-12-21 2018-12-21
US62/783,741 2018-12-21
PCT/CA2019/051884 WO2020124262A1 (en) 2018-12-21 2019-12-20 New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof

Publications (1)

Publication Number Publication Date
CA3124267A1 true CA3124267A1 (en) 2020-06-25

Family

ID=71100034

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3124267A Pending CA3124267A1 (en) 2018-12-21 2019-12-20 New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof

Country Status (6)

Country Link
US (1) US20220089531A1 (enExample)
EP (1) EP3898582A4 (enExample)
JP (1) JP2022515248A (enExample)
CN (1) CN113661158A (enExample)
CA (1) CA3124267A1 (enExample)
WO (1) WO2020124262A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4114371A4 (en) * 2020-03-05 2024-04-17 Centessa Pharmaceuticals (UK) Limited ALPHA-SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF
CA3174623A1 (en) * 2020-03-05 2021-09-10 Janpix, Ltd. Stat inhibitory compounds and compositions
CA3191657A1 (en) * 2020-09-04 2022-03-10 Roman FLECK Stat inhibitory compounds and compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960434B2 (en) * 2006-05-19 2011-06-14 University Of South Florida Small molecule inhibitors of STAT3 with anti-tumor activity
KR20130121818A (ko) * 2010-08-02 2013-11-06 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 Stat 단백질의 저해제로서의 치환된 2-히드록시-4-(2-(페닐설폰아미도)아세트아미도)벤조산 유사체
CN102219755B (zh) * 2011-05-05 2013-04-03 南京大学 Stat3的小分子选择性抑制剂及其制备方法和应用
US9650399B2 (en) * 2012-05-25 2017-05-16 The Governing Council Of The University Of Toronto Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
US9822135B2 (en) * 2012-10-30 2017-11-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 dimerization inhibitors
BR112016028022B1 (pt) * 2014-05-30 2023-03-28 The Governing Council Of The University Of Toronto Compostos de sulfonamida inibidores de stat5

Also Published As

Publication number Publication date
CN113661158A (zh) 2021-11-16
EP3898582A4 (en) 2022-08-24
EP3898582A1 (en) 2021-10-27
JP2022515248A (ja) 2022-02-17
WO2020124262A1 (en) 2020-06-25
US20220089531A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
KR101717098B1 (ko) 디글리시드 에테르 유도체 치료법 및 이의 사용 방법
JP6543366B2 (ja) 新しいサリチル酸誘導体、薬学上許容可能なその塩、その組成物及びその使用方法
JP6100439B2 (ja) アンドロゲン受容体調節薬のエステル誘導体およびそれらの使用のための方法
RU2639145C2 (ru) Производные оксотиоимидазолидина, способы их получения и их применение в медицине в качестве ингибиторов андрогенного рецептора
RU2727705C1 (ru) Производное бензопиперидина, способ его получения и его медицинское применение
JP2013537535A (ja) Ｓｔａｔタンパク質の阻害剤としての、置換２−ヒドロキシ−４−（２−（フェニルスルホンアミド）アセトアミド）安息香酸類似体
JP2021185193A (ja) インデニル化合物、医薬組成物、およびその医学的使用
JP2015533778A (ja) がんの治療のための新規フェニル−ピリジン／ピラジンアミド
WO2018154118A2 (en) Novel aromatic compounds
US20220089531A1 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
CN114149424A (zh) 用于治疗疾病的杂环化合物
WO2022249120A1 (ko) 신규한 벤조인돌론 화합물 및 이를 포함하는 약학적 조성물
JP2023103371A (ja) 新規の芳香族化合物
HK40063807A (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
EP4470608A1 (en) Lysophosphatidylserine analogue, and lysophosphatidylserine analogue-containing phamaceutical composition for treating or preventing fibrosis
HK40070316A (en) Heterocyclic compounds for the treatment of disease
HK40015967A (en) Inhibitors of the n-terminal domain of the androgen receptor
HK1260375A1 (en) Heterocyclic compounds for the treatment of disease